


# Association of two aggressive tumors: prolactinoma and multiple meningioma – difficult issue, difficult management

Georgiana Constantinescu<sup>1</sup>, Anamaria Bursuc<sup>1</sup>, Alina Daniela Belceanu<sup>1</sup>, Ioana Armașu<sup>1</sup>, Iulia Crumpei<sup>1</sup>, Vasile Ciubotaru<sup>2</sup>, Cristina Preda<sup>1</sup>, Carmen Vulpoi<sup>1</sup>

1 – Department of Endocrinology, University of Medicine and Pharmacy “Grigore T. Popa” Iași  
2- Department of Neurosurgery, Bagdasar Arseni Hospital, Bucharest

## Introduction

- ❑ Pituitary adenomas are common intracranial tumors mainly considered as benign.
- ❑ Rarely, these tumors can exhibit an aggressive behavior, invading surrounding tissues, presenting a resistance to conventional treatment leading to early and frequent recurrences.
- ❑ Even more rarely, pituitary tumors can give rise to cerebrospinal or systemic metastases, therefore being qualified as pituitary carcinomas.
- ❑ Pituitary carcinomas are exceedingly rare, with an incidence of 0.2% of symptomatic pituitary tumors [1].



- ❑ Meningioma are benign tumors that derive from arahnoid membrane, with higher frequency in females than males [2].
- ❑ The coexistence of pituitary adenoma and meningioma is very rare.
- ❑ The association between prolactinoma and meningioma is partly attributed to the existence of prolactin receptors at the level of meningioma [3]

## Case report

**2008**  
46 year old female patient with bitemporal hemianopsia no other clinical complaints

**MRI: pituitary macroadenoma (22/19/35mm) with suprasellar evolution**

**hormonal balance**

- hyperprolactinemia  
PRL= 66ng/dl - X 3N (N: 1.2-19 ng/dl)

=> **Cabergoline with good evolution**

- secondary thyroid and gonadal insufficiency  
TSH= 0,4 uUI/ml (N: 0.4-4uUI/ml)  
FSH= 7.3uUI/ml (N: 35- 151uUI/ml)  
LH = 3.5uUI/ml (N: 16-90uUI/ml)

**3 years later 2011**

- acute intracranial hypertension

↓

**Transcranial adenomectomy**

- Gamma knife radiation

↓

**subsequent adrenal insufficiency**

- Nodular goiter

↓

**partial thyroidectomy**

**4 years later 2015**


progressive tumor growth

↓

**second transcranial adenomectomy**



**Tumoral lesion with mixt structure: parenchymatous and chystic intra and extra sellar with extension in left cavernous sinus**



**MRI: nodular lesion with the aspect of meningioma Ponto-cerebral angle**

**1 year later 2016**

- intensive vertiginous syndrome
- second episode of acute intracranial hypertension

**MRI: two cerebral meningiomas**

One located at craniospinal junction =>urgent excision

**Hysto pathological:**

*Disseminated eosinophilic pituitary adenoma*

**Post op:** Left cranial nerves paresis X, XI, XII


**Remnant: aggressive pituitary adenoma vs meningioma**

**immunohistochemistry**

negative: Anti S100, anti CK, anti EMA  
low positive: anti NSE, anti Vim  
Ki 67= 2%

2016

Hormone	Values	Normal Values
TSH	0.221 uUI/ml	0.4-4uUI/ml
FT4 (under substitution)	0.880ng/dl	0.89-1.76ng/dl
Cortisol (under substitution)	2.97 ug/dl	5-25ug/dl
IGF	64 ng/ml	87-238ng/ml
FSH	0.67mIU/ml	21.7-153mIU/ml
PRL	15.1ng/ml	1.9-25ng/ml



## Discussions

- ❑ Pituitary adenoma express different receptors for Fibroblast growth factor FGF 1 and FGF2 . There is a high immunoreactivity towards circulatory FGF like in patients with sporadic pituitary adenoma and meningioma [3,4]. This fact could explain the association between adenoma and meningioma
- ❑ It is debatable if meningioma result as a consequence of hormone dependent growth or secondary to radiation, characterized by younger age at presentation, higher male-to-female ratio and biologically more aggressiveness compared to primary spontaneous meningioma [5].

## Conclusion

- ❑ Patient's evolution is marked by rapid and extensive tumor progression in spite of adequate treatment, consistent with an aggressive pituitary adenoma.
- ❑ Nevertheless, in our case we discuss about the association between prolactinoma and multiple meningioma versus aggressive pituitary tumor.
- ❑ Further histopathological and molecular markers could be helpful in establishing a firm diagnosis and targeted treatment.

### References:

- [1] Chatzellis E., Alexandraki K., Androulakis I., Kaltsas G., Aggressive pituitary tumors, Neuroendocrinology 2015;101:87-104 [2] Barnholtz-Sloan J., Kruchko C, Neurosurg Focus 23 (4):E2, 2007; [3] Muccioli G, Faccani C, Lanotte M, Forni M and Ciccarelli E; Prolactin receptors in human meningiomas: characterization and biological role J Endocrinol 1997 Jun;153(3):365-71; [4] Amit A, Achawal S, Dorward N. Pituitary macro adenoma and vestibular schwannoma: a case report of dual intracranial pathologies. Br J Neurosurg 2008;22:695-6.1; [5] Ueba T, Takahashi JA, Fukumoto M, Ohta M, Ito N, Oda Y, et al. Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. Neurosurgery 1994;34:221-5; [6] Strojan P, Popovic M, Jereb B, Secondary intracranial meningiomas after high-dose cranial irradiation: report of five cases and review of the literature, Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):65-73

